Author/Authors :
Per-Ola Johansson، نويسنده , , Marcus B?ck، نويسنده , , Ingemar Kvarnstr?m، نويسنده , , Katarina Jansson، نويسنده , , Lotta Vrang، نويسنده , , Elizabeth Hamelink، نويسنده , , Anders Hallberg، نويسنده , , Asa Rosenquist، نويسنده , , Bertil Samuelsson، نويسنده ,
Abstract :
The HCV NS3 protease is essential for replication of the hepatitis C virus (HCV) and therefore constitutes a promising new drug target for anti-HCV therapy. Several potent and promising HCV NS3 protease inhibitors, some of which display low nanomolar activities, were identified from a series of novel inhibitors incorporating a trisubstituted cyclopentane dicarboxylic acid moiety as a surrogate for the widely used N-acyl-(4R)-hydroxyproline in the P2 position.
Keywords :
HCV , Protease inhibitor , NS3 , Cyclopentane-derived P2 scaffold